Escherichia (e.g., E. Coli, Etc.) Or Salmonella Patents (Class 435/252.8)
  • Publication number: 20120149090
    Abstract: The invention provides a cell for preparing competent cells, wherein the cell is capable of spontaneously accumulating self-producing trehalose therein and the cell is used for the preparation of competent cells. The invention also provides a method for preparing competent cells, including: culturing the cell for preparing the competent cell mentioned previously to obtain a cell suspension; placing the cell suspension into an ice bath; centrifuging the cell suspension to obtain a cell precipitate; mixing a transform reagent with the cell precipitate; and obtaining competent cells suspension.
    Type: Application
    Filed: December 27, 2010
    Publication date: June 14, 2012
    Inventors: Jia-Hung WANG, Meng-Yin TSAI, Ting-Ting HUNG, Kelly TENG
  • Publication number: 20120149115
    Abstract: The present invention relates to a method for genomic DNA rearrangements, and more particularly, to a method for deletion, duplication, inversion, replacement, or rearrangement of genomic DNA using pairs of site-specific nucleases targeting two or more sites in the genome, a cell in which genomic DNA is deleted, duplicated, inverted, replaced, or rearranged by the same method, and a method for expressing the site-specific nucleases in cells. Further, the present invention relates to a method for inserting synthetic DNA molecules into the genome using site-specific nucleases targeting a pre-determined site in the genome, a cell in which DNA insertion occurs by the same method, and a method for expressing the site-specific nucleases in cells.
    Type: Application
    Filed: June 11, 2010
    Publication date: June 14, 2012
    Applicants: SNU R&DB FOUNDATION, TOOLGEN INCORPORATION
    Inventors: Jin Soo Kim, Hyung Joo Lee, Eun Ji Kim
  • Patent number: 8198044
    Abstract: The invention relates to compositions and methods for the in vivo production of polypeptides comprising one or more unnatural amino acids. Specifically, the invention provides plasmid systems for the efficient eubacterial expression of polypeptides comprising one or more unnatural amino acids at genetically-programmed positions.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: June 12, 2012
    Assignee: The Scripps Research Institute
    Inventors: Youngha Ryu, Peter G. Schultz
  • Publication number: 20120141443
    Abstract: The present invention generally relates to the field of bacteria. In particular, the present invention concerns “short time high temperature” treated probiotics and/or dairy starter cultures and applications of these bacteria. One embodiment of the present invention relates to “short-time high temperature” treated probiotics and/or dairy starter cultures and their use to prepare compositions to treat or prevent inflammatory disorders.
    Type: Application
    Filed: May 7, 2010
    Publication date: June 7, 2012
    Applicant: NESTEC S.A.
    Inventors: Guenolee Prioult, Annick Mercenier
  • Publication number: 20120137752
    Abstract: Hydrotesting fluid compositions including stable populations of corrosion reducing microbes, where the populations are is sufficient to reduce or eliminate microbiologically influenced corrosion (MIC).
    Type: Application
    Filed: September 27, 2011
    Publication date: June 7, 2012
    Applicants: WEATHERFORD/LAMB, INC.
    Inventor: Michael Morrow
  • Patent number: 8187850
    Abstract: The present invention provides a method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family, particularly a bacterium belonging to genus Escherichia or Pantoea, which has been modified to attenuate expression of the ybiV gene.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: May 29, 2012
    Assignee: Ajinomoto Co., Inc.
    Inventors: Konstantin Vyacheslavovich Rybak, Marina Evgenievna Sheremet'eva, Aleksandra Yurievna Skorokhodova, Tatyana Viktorovna Leonova, Yury Ivanovich Kozlov, Vitaly Grigorievich Paraskevov, legal representative
  • Publication number: 20120124898
    Abstract: This invention provides co-cultures of photosynthetic microorganisms and biofuel producing microorganisms. In certain embodiments, polysaccharide-producing, photosynthetic microorganisms are microalgae having frustules provide a substrate on which biofuel-producing microorganisms can grow. In other embodiments, the photosynthetic microorganisms produce a lipid and the non-photosynthetic microorganisms produce a solvent in which the lipid is soluble.
    Type: Application
    Filed: July 21, 2011
    Publication date: May 24, 2012
    Inventor: Pamela R. Contag
  • Publication number: 20120114698
    Abstract: The present invention relates to a Salmonella strain suitable as a marker vaccine having an inactivated gene.
    Type: Application
    Filed: November 20, 2009
    Publication date: May 10, 2012
    Inventor: Heiko Apfel
  • Publication number: 20120100116
    Abstract: The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.
    Type: Application
    Filed: April 2, 2010
    Publication date: April 26, 2012
    Applicants: THOMAS JEFFERSON UNIVERSITY, INSTITUT PASTEUR
    Inventors: Christophe Prehaud, Monique Lafon, Matthias Johannes Schnell
  • Publication number: 20120100591
    Abstract: Fermentation products (e.g., bioproducts such as hydrocarbons and other organic compounds) are produced from biomass or gases through digestion and fermentation under conditions that thermodynamically favor production of the fermentation products.
    Type: Application
    Filed: December 3, 2010
    Publication date: April 26, 2012
    Inventor: Richard Allen Kohn
  • Publication number: 20120093869
    Abstract: The present invention relates to compositions and methods for disease treatment and prevention through administration of a live attenuated composition. In particular, the present invention provides compositions and methods for the treatment and prevention of urinary tract infection by administration of a live attenuated compositions lacking O-antigen ligase activity.
    Type: Application
    Filed: May 14, 2010
    Publication date: April 19, 2012
    Inventors: David Klumpp, Anthony Schaeffer, Benjamin Billips
  • Patent number: 8153414
    Abstract: The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: April 10, 2012
    Assignee: Allertein Therapeutics, LLC
    Inventors: Michael J. Caplan, Hugh A. Sampson, A. Wesley Burks, H. Kim Bottomly, Howard B. Sosin
  • Patent number: 8148107
    Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: April 3, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt
  • Publication number: 20120077241
    Abstract: The invention relates to bacterium that have increased resistance to furfural and methods of preparation. The invention also relates to methods of producing ethanol using the bacterium and corresponding kits.
    Type: Application
    Filed: January 4, 2010
    Publication date: March 29, 2012
    Applicant: University of Florida Research Foundation, Inc.
    Inventors: Elliot Norman Miller, Laura R. Jarboe, Lorraine P. Yomano, Sean W. York, Keelnatham Shanmugam, Lonnie O'Neil Ingram
  • Publication number: 20120077181
    Abstract: The cryopreservation of cells and tissue cultures for long term storage of cells, cell constructs or three-dimensional complex tissues assemblies is based on the use of a collagen cell carrier (CCC) having a specific composition and thickness and appropriate mechanical properties which are maintained after thawing. The collagen cell carrier provides a suitable support for the cryopreservation resulting in high survival rates after thawing and providing cells and tissue assemblies already adhered to a mechanically stable and biocompatible support. Frozen collagen carrier-cells assemblies, the frozen artificial cell constructs or three-dimensional complex tissue assemblies obtainable by the method and the use thereof after thawing are also disclosed.
    Type: Application
    Filed: February 18, 2010
    Publication date: March 29, 2012
    Inventors: Timo Schmidt, Lothar Just, Franz Maser, Holger Becker
  • Publication number: 20120058531
    Abstract: The present invention concerns a new method for the production of 1,3-propanediol comprising culturing a microorganism on a culture medium with high glycerine content. The invention also concerns a new microorganism, or strain of microorganism, adapted for the production of 1,3-propanediol from medium comprising high glycerine content. The invention also concerns an “adapted microorganism” which glycerol metabolism is directed to 1,3-propanediol production, and which is allowed to grow in the presence of a high concentration of industrial glycerine. The invention also concerns a biosourced 1,3-propanediol obtained by the process thereof. Finally the invention concerns the use of the above described biosourced 1,3-propanediol as extender chain in thermoplastic polyurethane, as monomers in polytrimethylene terephtalate and as a component in cosmetics formulations.
    Type: Application
    Filed: May 5, 2010
    Publication date: March 8, 2012
    Applicant: METABOLIC EXPLORER
    Inventors: Michel Chateau, Jean-Yves Dubois, Philippe Soucaille
  • Publication number: 20120058087
    Abstract: The present invention relates to methods for diagnosing and treatment of a dormant infection of at least one pathogen. The invention further relates to a composition comprising an anti-dormancy factor as well as to said composition for use in a method of diagnosis or treatment and also to a method for manufacturing said composition. The invention further relates to a kit of parts comprising, inter alia, said composition. The invention also relates to a method for activating a dormant infection.
    Type: Application
    Filed: December 18, 2009
    Publication date: March 8, 2012
    Applicant: Kobenhavns Universitet
    Inventors: Morten Rønn Petersen, Anders Miki Bojesen
  • Publication number: 20120053155
    Abstract: A system and method for reverting the antibiotic tolerance of persister cells. Brominated furanones, which are quorum sensing inhibitors, are used to revert the antibiotic tolerance of persister cells and enhance their susceptibility to antibiotics by up to one hundred fold. Brominated furanones can be used against bacterial persister cells in biofilms or planktonic form.
    Type: Application
    Filed: August 9, 2011
    Publication date: March 1, 2012
    Applicant: Syracuse University
    Inventors: Dacheng Ren, Jiachuan Pan
  • Publication number: 20120052093
    Abstract: The present invention relates to methods and compositions for preventing and treating uterine disease, and in particular to vaccines and bacteriophage compositions for treating or preventing puerperal metritis, clinical endometritis and/or subclinical endometritis.
    Type: Application
    Filed: April 22, 2010
    Publication date: March 1, 2012
    Applicant: CORNELL UNIVERSITY
    Inventor: Rodrigo Carvalho Bicalho
  • Publication number: 20120045475
    Abstract: The present invention relates to a bacterium attenuated by a mutation in at least one ABC transporter gene wherein the mutation renders the corresponding ABC transporter protein non-functional and wherein the attenuated bacterium persists in a subject.
    Type: Application
    Filed: February 17, 2010
    Publication date: February 23, 2012
    Applicant: AUSTRALIAN POULTRY CRC PTY LIMITED
    Inventors: Glenn Francis Browning, Philip Francis Markham, Chi-Wen Tseng
  • Patent number: 8119365
    Abstract: A bacteria lacking genomic and non-genomic IS elements is provided. The bacteria may be more stable and useful for the production of amino acids, polypeptides, nucleic acids and other products.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: February 21, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Frederick R. Blattner, John W. Campbell, David Frisch, Guy Plunkett, Gyorgy Posfai
  • Patent number: 8119373
    Abstract: In the method for separating and purifying histidine from a culture containing the amino acid, the culture containing histidine and microbial cells is charged onto the top of a column filled with a carrier particle whose particle size is 420 ?m or more and which has an ability to adsorb histidine and then an eluent is passed through the column whereby accomplishing the separation and purification of histidine, and preferably in the step mentioned above, a strong acid cation exchange resin is employed as a carrier particle whereby accomplishing the separation and purification of histidine.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: February 21, 2012
    Assignee: Kyowa Hakko Bio Co., Ltd.
    Inventors: Hideki Murata, Noboru Fujii, Kenji Tajima
  • Patent number: 8114654
    Abstract: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases, which incorporate redox active amino acids into proteins are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with redox active amino acids using these orthogonal pairs.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: February 14, 2012
    Assignee: The Scripps Research Institute
    Inventors: Lital Alfonta, Peter G. Schultz, Zhiwen Zhang
  • Patent number: 8114649
    Abstract: L-cysteine is produced by culturing an Escherichia bacterium having L-cysteine producing ability and containing a gene encoding an O-acetylserine sulphydrylase B or MalY regulatory protein that is modified so that cysteine desulfhydrase activity is reduced or eliminated. The bacterium is cultured in a medium to produce and cause accumulation of L-cysteine in the medium, and collecting L-cysteine from the medium.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: February 14, 2012
    Assignee: Ajinomoto Co., Inc.
    Inventors: Hiroshi Takagi, Shigeru Nakamori, Masaru Wada, Hirotada Mori
  • Patent number: 8110670
    Abstract: Genetically engineered cells and microorganisms are provided that produce products from the fatty acid biosynthetic pathway (fatty acid derivatives), as well as methods of their use. The products are particularly useful as biofuels.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: February 7, 2012
    Assignee: LS9, Inc.
    Inventors: Zhihao Hu, Fernando Valle
  • Patent number: 8101168
    Abstract: The invention provides an attenuated enterobacterium comprising an attenuating mutation in the fnr gene, and optionally further comprising a heterologous nucleic acid encoding a foreign antigen. Also provided are pharmaceutical formulations comprising the attenuated enterobacteria of the invention. Further disclosed are methods of inducing an immune response in a subject by administration of an immunogenically effective amount of an attenuated enterobacterium or pharmaceutical formulation of the invention.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: January 24, 2012
    Assignee: North Carolina State University
    Inventors: Hosni M. Hassan, Ryan C. Fink, Matthew R. Evans
  • Publication number: 20120015426
    Abstract: Disclosed are novel bacterial hosts that are capable of high efficiency transformation with methylated and/or unmethylated nucleic acids, and that are bacteriophage resistant. Such bacteria contain: (1) an F? episome that confers high efficiency transformability; (2) one or more mutations that allow transformation of methylated nucleic acids; (3) one or more mutations that allow transformation with unmethylated nucleic acids; and/or (4) one or more mutations that confer resistance to bacteriophage infection. Also disclosed are methods for transforming such bacteria, and kits that contain such bacteria (e.g., that have been made competent for transformation).
    Type: Application
    Filed: September 27, 2011
    Publication date: January 19, 2012
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Fredric R. BLOOM, Brian Schmidt
  • Patent number: 8097437
    Abstract: The instant invention provides highly pure Polysialic acid and process for preparation thereof.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: January 17, 2012
    Assignee: Serum Institute of India Ltd.
    Inventors: Subhash V. Kapre, Umesh Shaligram
  • Publication number: 20120003740
    Abstract: This document discloses electroporation vessels, electrocompetent cells that have been aliquoted and frozen in electroporation vessels, and a number of other apparatuses, kits, and methods for electroporation. Some embodiments of electroporation vessels described herein may include a pair of opposing walls that are downwardly angled toward one another in a gap between two electrode surfaces. Further embodiments of devices and methods described herein may eliminate the need for an end user to transfer competent cells from a capped tube to electroporation cuvette, thereby saving time and producing less waste.
    Type: Application
    Filed: December 28, 2010
    Publication date: January 5, 2012
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Laura Vozza-Brown, Harry Yim, John Cameron, Matthew O'Banion, Adam Scott Henry, Lisa Marie Olivier
  • Publication number: 20120003626
    Abstract: The present disclosure describes methods for concentrating microorganisms with concentration agents in a sampling device and the sampling device described herein. More specifically, methods for concentrating microorganisms from large volume samples with concentration agents in a sampling device can provide for rapid, low cost, simple (involving no complex equipment or procedures), and/or effective processes under a variety of conditions.
    Type: Application
    Filed: December 30, 2009
    Publication date: January 5, 2012
    Inventors: Manjiri T. Kshirsagar, Kurt J. Halverson, Neil Percy, James E. Aysta
  • Patent number: 8088620
    Abstract: The invention relates to optimised micro-organism strains for the biotransformation production of molecules having NADPH-consuming biosynthetic pathways. The inventive strains can be used in NADPH-consuming biotransformation methods. Said strains are characterized in that one or more NADPH-oxidizing activities are limited.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: January 3, 2012
    Assignee: Metabolic Explorer
    Inventors: Gwénaëlle Bestel-Corre, Cédric Boisart, Michel Chateau, Benjamin Gonzalez, Philippe Soucaille, Rainer Figge, Olivier Zink
  • Publication number: 20110313206
    Abstract: Methods for the fermentative production of four carbon alcohols is provided. Specifically, butanol, preferably isobutanol is produced by the fermentative growth of a recombinant bacterium expressing an isobutanol biosynthetic pathway.
    Type: Application
    Filed: December 13, 2010
    Publication date: December 22, 2011
    Applicant: BUTAMAX(TM) ADVANCED BIOFUELS LLC
    Inventors: GAIL K. DONALDSON, ANDREW C. ELIOT, DENNIS FLINT, LORI ANN MAGGIO-HALL, VASANTHA NAGARAJAN
  • Patent number: 8080395
    Abstract: An isolated mutant of coryneform bacteria comprising a gene encodes a polypeptide having 2-methylcitrate dehydratase activity, where the polypeptide comprises an amino acid sequence in which one of the proteinogenic amino acids except L-proline is present at position 272 or a corresponding or comparable position. In addition, an isolated polynucleotide encoding a polypeptide having 2-methylcitrate dehydratase enzymic activity, which comprises at position 272 of the amino acid sequence or a corresponding or comparable position a proteinogenic amino acid except L-proline is described. A method for producing a recombinant coryneform bacterium and L-amino acids. A recombinant microorganism, L-Lysine-containing feed additive, and L-Tryptophan-containing feed additive is also described.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: December 20, 2011
    Assignee: Evonik Degussa GmbH
    Inventors: Brigitte Bathe, Caroline Kreutzer, Georg Thierbach
  • Publication number: 20110306083
    Abstract: Methods are provided for selecting microbial strains with improved properties for fermentation and/or bioproduct production. A salt selection is employed to identify mutants with improved bioproduct tolerance, titer, or osmotic tolerance relative to a microbial strain from which they were derived.
    Type: Application
    Filed: June 13, 2011
    Publication date: December 15, 2011
    Applicant: Cobalt Technologies, Inc.
    Inventor: Jeanette M. MUCHA
  • Patent number: 8076111
    Abstract: An organic acid is produced by allowing a bacterium which has an ability to produce an organic acid and has been modified so that expression of yidE gene is enhanced, or a product obtained by processing the bacterium, to act on an organic raw material in a reaction mixture containing carbonate ions, bicarbonate ions, or carbon dioxide gas to produce the organic acid, and collecting the organic acid.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: December 13, 2011
    Assignee: Ajinomoto Co., Inc.
    Inventors: Keita Fukui, Yoshinori Tajima, Kazue Kawamura, Yoshihiro Usuda, Kazuhiko Matsui
  • Patent number: 8071339
    Abstract: The present invention relates to a mutant bacterial PRPP synthetase which is resistant to feedback by purine nucleotides, and a method for producing L-histidine using the bacterium of the Enterobacteriaceae family wherein the L-amino acid productivity of said bacterium is enhanced by use of the PRPP synthetase which is resistant to feedback by purine nucleotides, coded by the mutant prsA gene.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: December 6, 2011
    Assignee: Ajinomoto Co., Inc.
    Inventors: Elena Vitalievna Klyachko, Rustem Saidovich Shakulov, Yuri Ivanovich Kozlov
  • Patent number: 8067179
    Abstract: Methods and compositions for the screening and isolation of ligand-binding polypeptides, such as antibodies. In some aspects, methods of the invention enable the isolation of intact soluble antibodies comprising a constant domain. Screening methods that employ genetic packages such as bacteria and bacteriophages enable high through-put identification of ligand binding molecules.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: November 29, 2011
    Assignee: Research Development Foundation
    Inventors: George Georgiou, Yariv Mazor
  • Publication number: 20110286916
    Abstract: The present invention relates to mammalian antibodies, preferably fully human monoclonal antibodies and antigen-binding portions thereof that specifically bind to a cell surface receptor, wherein the receptor protein is a Notch1 receptor protein. Some of the disclosed antibodies bind Notch1 to the exclusion of other members of the Notch receptor family, while other antibodies bind Notch 1 and Notch3. Nucleic acid molecules encoding the Notch antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of Notch1 or Notch3 including aberrant activation of each of these receptors.
    Type: Application
    Filed: November 16, 2009
    Publication date: November 24, 2011
    Inventors: Jose Miguel Aste-Amezaga, Ningyan Zhang, Fubao Wang, Andrew Bett, Anna Demartis, Maurizio Nuzzo, Paolo Monaci, Stephen Blacklow, Jon Aster
  • Publication number: 20110269198
    Abstract: The invention pertains to a method for preparing cells that can be used as biocatalysts by inducing in them a growth-decoupled state, in which interferase inhibits the expression of genes except the ones that code for the pathway enzymes of interest. mRNAs that code for interferase-resistant products are overexpressed in the background of a metabolically-frozen cell. Enzymes that compete for a substrate or product of the pathway of interest may be altered such that the enzyme is sensitive to a site-specific protease, which protease is inducible in the host cell.
    Type: Application
    Filed: December 14, 2009
    Publication date: November 3, 2011
    Applicant: GREENLIGHT BIOSCIENCES, INC.
    Inventor: Daniel Klein-Marcuschamer
  • Publication number: 20110269213
    Abstract: Novel fungal endoglucanases Cel5 and Cel2 are disclosed. The endoglucanases are conveniently produced by recombinant technology, and means for their production are described. The endoglucanases are used for treating cellulosic material, especially in textile industry, e.g. in biofinishing or biostoning. They may also be used in detergents, in animal feed and/or in pulp and paper industry, or in hydrolysis of lignocellulosic material for, e.g. bioethanol production.
    Type: Application
    Filed: December 28, 2009
    Publication date: November 3, 2011
    Inventors: Terhi Puranen, Leena Valtakari, Marika Alapuranen, George Szakacs, Pentti Ojapalo, Jari Vehmaanperä
  • Publication number: 20110269212
    Abstract: Novel fungal endoglucanases with substantial performance at low temperatures are disclosed. The endoglucanases are conveniently produced by recombinant technology, and means for their production are described. The endoglucanases are used for treating cellulosic material, especially in textile industry, e.g. in biofinishing or biostoning. They may also be used in detergents, in animal feed and/or in pulp and paper industry or bioethanol production.
    Type: Application
    Filed: December 28, 2009
    Publication date: November 3, 2011
    Applicant: AB Enzymes Oy
    Inventors: Leena Valtakari, Marika Alapuranen, George Szakacs, Jarno Kallio, Pentti Ojapalo, Jari Vehmaanperä, Terhi Puranen
  • Publication number: 20110268773
    Abstract: The present invention relates to an isolated inclusion body comprising a polypeptide, characterised in that such inclusion body is in particulate form. The present invention also refers to a bacterial cell comprising said inclusion body. The present invention additionally refers to a composition comprising said inclusion body and a eukaryotic cell. The present invention moreover refers to a composition comprising said inclusion body and animal or plant tissue. The present invention furthermore refers to the uses of said inclusion body as medicaments and cell-proliferation stimulators and tissue regenerators.
    Type: Application
    Filed: December 22, 2009
    Publication date: November 3, 2011
    Applicants: UNIVERSITAT AUTÒNOMA DE BARCELONA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS
    Inventors: Jaume Veciana Miro, Inmaculada Ratera Bastardas, César Díez Gil, Antonio Pedro Villaverde Corrales, Esther Vázquez Gómez, Elena García Fruitós
  • Publication number: 20110262410
    Abstract: The present invention relates to the use of F4+ non-pathogenic Escherichia coli strains to promote growth in an animal. The present invention also relates to the use of such strains to homogenize growth among a herd of animals. More specifically, the animal(s) of interest in the present invention are those wherein growth promotion or growth homogenization are desired goals, such as animals reared for meat production. The present invention further relates to a method for promoting growth of an animal as well as a method for homogenizing growth among a herd of animals.
    Type: Application
    Filed: July 8, 2011
    Publication date: October 27, 2011
    Applicant: Valorisation - Recherche, Limited Partnership
    Inventors: Eric Nadeau, John Morris Fairbrother
  • Patent number: 8043842
    Abstract: The present invention provides a bacterium having a genome that is genetically engineered to be at least 2 to 14% smaller than the genome of its native parent strain. A bacterium with a smaller genome can produce a commercial product more efficiently. The present invention also provides methods for deleting genes and other DNA sequences from a bacterial genome. The methods provide precise deletions and seldom introduces mutations to the genomic DNA sequences around the deletion sites. Thus, the methods can be used to generate a series of deletions in a bacterium without increasing the possibility of undesired homologous recombination within the genome. In addition, some of the methods provided by the present invention can also be used for replacing a region of a bacterial genome with a desired DNA sequence.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: October 25, 2011
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Frederick R. Blattner, Gyorgy Posfai, Christopher D. Herring, Guy Plunkett, Jeremy D. Glasner
  • Publication number: 20110256576
    Abstract: The present invention is directed to the recovery of bacteria and microparasites, particularly Cryptosporidium and Giardia, from water samples by filtration through a mixed cellulose ester membrane, partial dissolution of said membrane with methanol followed by completion in the presence of acetone, and purification and concentration using glass beads as a secondary confinement matrix.
    Type: Application
    Filed: October 14, 2009
    Publication date: October 20, 2011
    Applicant: Universite Laval
    Inventors: Luc Bissonnette, Andrée F. Maheux, Michel G. Bergeron, Maurice Boissinot, Jean-Luc Bernier
  • Publication number: 20110256583
    Abstract: A reagent mixture and testing procedure for accelerating mixing of the formulation with a specimen sample being tested by effervescing when hydrolized, thereby causing an internal “stirring” of the reagent and the specimen sample. Examples of specimen samples that can be tested include nasal swabs and lesion swabs, environmental swabs, foodstuffs, and water, to mention a few.
    Type: Application
    Filed: March 23, 2011
    Publication date: October 20, 2011
    Inventor: Stephen C. Edberg
  • Patent number: 8039243
    Abstract: The present invention provides a bacterium having a genome that is genetically engineered to be smaller than the genome of its native parent strain. A bacterium with a smaller genome can produce a commercial product more efficiently. The present invention also provides methods for deleting genes and other DNA sequences from a bacterial genome. The methods provide precise deletions and seldom introduces mutations to the genomic DNA sequences around the deletion sites. Thus, the methods can be used to generate a series of deletions in a bacterium without increasing the possibility of undesired homologous recombination within the genome. In addition, some of the methods provided by the present invention can also be used for replacing a region of a bacterial genome with a desired DNA sequence.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: October 18, 2011
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Frederick R. Blattner
  • Publication number: 20110236929
    Abstract: The present invention relates to a novel non-pathogenic Escherichia coli (E. coli) B BL21 strain comprising a deletion of group II capsular gene cluster, and the use thereof for the production of peptides.
    Type: Application
    Filed: November 10, 2009
    Publication date: September 29, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Helle Fabricius Wöldike, Jianhui Deng, Xin Zhao, Yun Liu, Jing Su
  • Publication number: 20110224097
    Abstract: Viable Gram-negative bacteria or components thereof comprising outer membranes that substantially lack a ligand, such as Lipid A or 6-acyl lipidpolysaccharide, that acts as an agonist of TLR4/MD2. The bacteria may comprise reduced activity of arabinose-5-phosphate isomerases and one or more suppressor mutations, for example in a transporter thereby increasing the transporters capacity to transport Lipid IVA or in membrane protein YhjD. One or more genes (e.g., IpxL, IpxM, pagP, IpxP, and/or eptA) may be substantially deleted and/or one or more enzymes (e.g., LpxL, LpxM, PagP, LpxP, and/or EptA) may be substantially inactive. The bacteria may be competent to take up extracellular DNA, may be donor bacteria, or may be members of a library. The present invention also features methods of creating and utilizing such bacteria.
    Type: Application
    Filed: March 11, 2011
    Publication date: September 15, 2011
    Applicant: RESEARCH CORPORATION TECHNOLOGIES
    Inventors: David Bramhill, Uwe Mamat
  • Publication number: 20110212458
    Abstract: The invention provides biosynthetic routes to xylitol production that do not require pure D-xylose for synthesis and that can utilize inexpensive substrates such as hemicellulose hydrolysates.
    Type: Application
    Filed: May 11, 2011
    Publication date: September 1, 2011
    Inventors: Paul Taylor, Ian Fotheringham, Nathan Wymer, Badal Saha, David Demirjian, Yoshikiyo Sakaibara, Francis Michael Racine